Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE

Next Previous
X
Search
Trial Profile

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infigratinib (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROPEL OLE
  • Sponsors QED Therapeutics

    • Most Recent Events

    • 09 Aug 2024 Planned number of patients changed from 230 to 300.
    • 18 Jun 2023 Trial design presented at the 105th Annual Meeting of the Endocrine Society.
    • 08 Jun 2023 According to BridgeBio media release, the company will present additional data ENDO 2023 from its achondroplasia program (PROPEL, PROPEL 2 and PROPEL OLE studies)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top